Modafinil improves cognition and attentional set shifting in patients with chronic schizophrenia

Neuropsychopharmacology

Volumn 29, Issue 7, 2004, Pages 1363-1373

  Turner, Danielle C ^a   Clark, Luke ^b   Pomarol Clotet, Edith ^a   McKenna, Peter ^a   Robbins, Trevor W ^b   Sahakian, Barbara J ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b UK   (United Kingdom)

Author keywords

Dopamine; Executive function; Impulsivity; Norepinephrine; Psychosis; Working memory

Indexed keywords

CLOZAPINE; MODAFINIL; NEUROLEPTIC AGENT; OLANZAPINE; PIPOTIAZINE; PLACEBO;

ADULT; ARTICLE; ATTENTION; ATTENTION DEFICIT DISORDER; CLINICAL ARTICLE; CLINICAL TRIAL; COGNITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFECT; FEMALE; HUMAN; LATENT PERIOD; MALE; PLANNING; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPONSE TIME; SCHIZOPHRENIA; TASK PERFORMANCE; VERBAL MEMORY;

ADULT; ANALYSIS OF VARIANCE; ATTENTION; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; BENZHYDRYL COMPOUNDS; CASE-CONTROL STUDIES; CHI-SQUARE DISTRIBUTION; CHRONIC DISEASE; COGNITION; COGNITION DISORDERS; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MEMORY, SHORT-TERM; MIDDLE AGED; NEUROPROTECTIVE AGENTS; NEUROPSYCHOLOGICAL TESTS; PATTERN RECOGNITION, VISUAL; PSYCHIATRIC STATUS RATING SCALES; REACTION TIME; SCHIZOPHRENIA; SPATIAL BEHAVIOR;

EID: 2942685608     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.npp.1300457     Document Type: Article

References (83)

1. Addington J, Addington D, Gasbarre L (2001). Neurocognitive and social functioning in schizophrenia and other diagnoses. Schizophr Res 48: 367-368.
2. American Psychiatric Association (1994). Diagnostic and Statistical Manual of Mental Disorders, 4th edn American Psychiatric Press: Washington, DC.
3. Andreasen NC, Flaum M, Arndt S (1992). The comprehensive assessment of symptoms and history (CASH). An instrument for assessing diagnosis and psychopathology. Arch Gen Psychiatry 49: 615-623.
4. Angrist B, Peselow E, Rubinstein M, Corwin J, Rotrosen J (1982). Partial improvement in negative schizophrenic symptoms after amphetamine. Psychopharmacology (Berl) 78: 128-130.
5. Aron AR, Dowson JH, Sahakian BJ, Robbins TW (2003a). Methylphenidate improves response inhibition in adults with attention-deficit/hyperactivity disorder. Biol Psychiatry 54: 1465-1468.
6. Aron AR, Fletcher PC, Bullmore ET, Sahakian BJ, Robbins TW (2003b). Stop-signal inhibition disrupted by damage to right inferior frontal gyrus in humans. Nat Neurosci 6: 115-116.
7. Badcock JC, Michie PT, Johnson L, Combrinck J (2002). Acts of control in schizophrenia: dissociating the components of inhibition. Psychol Med 32: 287-297.
8. Bechara A, Tranel D, Damasio AR (2002). The somatic marker hypothesis and decision-making. In J. Grafman (ed). Handbook of Neuropsychology, 2nd edn, Vol. 7. Elsevier Science BV: Amsterdam. pp 117-143.
9. Bond A, Lader M (1974). The use of analogue scales in rating subjective feelings. Br J Med Psychol 47: 211-218.
10. Buchanan RW, Holstein C, Breier A (1994). The comparative efficacy and long-term effect of clozapine treatment on neuropsychological performance. Biol Psychiatry 36: 717-725.
11. Caldwell Jr JA, Caldwell JL, Smythe III NK, Hall KK (2000). A double-blind, placebo-controlled investigation of the efficacy of modafinil for sustaining the alertness and performance of aviators: a helicopter simulator study. Psychopharmacology (Berl) 150: 272-282.
12. Carpenter MD, Winsberg BG, Camus LA (1992). Methylphenidate augmentation therapy in schizophrenia. J Clin Psychopharmacol 12: 273-275.
13. Cassens G, Inglis AK, Appelbaum PS, Gutheil TG (1990). Neuroleptics: effects on neuropsychological function in chronic schizophrenic patients. Schizophr Bull 16: 477-499.
14. Chemelli RM, Willie JT, Sinton CM, Elmquist JK, Scammell T, Lee C et al (1999). Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation. Cell 98: 437-451.
15. Chiarello RJ, Cole JO (1987). The use of psychostimulants in general psychiatry. A reconsideration. Arch Gen Psychiatry 44: 286-295.
16. Davidson M, Keefe RS (1995). Cognitive impairment as a target for pharmacological treatment in schizophrenia. Schizophr Res 17: 123-129.
17. Deroche-Gamonet V, Darnaudery M, Bruins-Slot L, Piat F, Le Moal M, Piazza PV (2002). Study of the addictive potential of modafinil in naive and cocaine-experienced rats. Psychopharmacology (Berl) 161: 387-395.
18. Elliott R, McKenna PJ, Robbins TW, Sahakian BJ (1995). Neuropsychological evidence for frontostriatal dysfunction in schizophrenia. Psychol Med 25: 619-630.
19. Elliott R, Sahakian BJ, Matthews K, Bannerjea A, Rimmer J, Robbins TW (1997). Effects of methylphenidate on spatial working memory and planning in healthy young adults. Psychopharmacology (Berl) 131: 196-206.
20. Endicott J, Spitzer RL, Fleiss JL, Cohen J (1976). The global assessment scale. A procedure for measuring overall severity of psychiatric disturbance. Arch Gen Psychiatry 33: 766-771.
21. Evenden JL (1999). Varieties of impulsivity. Psychopharmacology (Berl) 146: 348-361.
22. Ferraro L, Antonelli T, O'Connor WT, Tanganelli S, Rambert FA, Fuxe K (1997). Modafinil: an antinarcoleptic drug with a different neurochemical profile to D-amphetamine and dopamine uptake blockers. Biol Psychiatry 42: 1181-1183.
23. Folstein MF, Folstein SE, McHugh PR (1975). 'Mini-mental state'. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12: 189-198.
24. Garety PA, Kuipers E, Fowler D, Freeman D, Bebbington PE (2001). A cognitive model of the positive symptoms of psychosis. Psychol Med 31: 189-195.
25. Goldberg TE, Bigelow LB, Weinberger DR, Daniel DG, Kleinman JE (1991). Cognitive and behavioral effects of the coadministration of dextroamphetamine and haloperidol in schizophrenia. Am J Psychiatry 148: 78-84.
26. Goldberg TE, Egan MF, Gscheidle T, Coppola R, Weickert T, Kolachana BS et al (2003). Executive subprocesses in working memory: relationship to catechol-O-methyltransferase Val158Met genotype and schizophrenia. Arch Gen Psychiatry 60: 889-896.
27. Goldberg TE, Greenberg RD, Griffin SJ, Gold JM, Kleinman JE, Pickar D et al (1993). The effect of clozapine on cognition and psychiatric symptoms in patients with schizophrenia. Br J Psychiatry 162: 43-48.
28. Goldberg TE, Weinberger DR, Berman KF, Pliskin NH, Podd MH (1987). Further evidence for dementia of the prefrontal type in schizophrenia? A controlled study of teaching the Wisconsin Card Sorting Test. Arch Gen Psychiatry 44: 1008-1014.
29. Green MF (1996). What are the functional consequences of neurocognitive deficits in schizophrenia? Am J Psychiatry 153: 321-330.
30. Green MF, Kern RS, Braff DL, Mintz J (2000). Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the 'right stuff'? Schizophr Bull 26: 119-136.
31. Hartman M, Steketee MC, Silva S, Lanning K, Andersson C (2003). Wisconsin card sorting test performance in schizophrenia: the role of working memory. Schizophr Res 63: 201-217.
32. Harvey PD, Geyer MA, Robbins TW, Krystal JH (2003). Cognition in schizophrenia: from basic science to clinical treatment. Psychopharmacology (Berl) 169: 213-214.
33. Heaton RK, Gladsjo JA, Palmer BW, Kuck J, Marcotte TD, Jeste DV (2001). Stability and course of neuropsychological deficits in schizophrenia. Arch Gen Psychiatry 58: 24-32.
34. Howell DC (1997). Statistical Methods for Psychology, 4th edn. Wadsworth Publishing Company: London.
35. Hutton SB, Puri BK, Duncan LJ, Robbins TW, Barnes TR, Joyce EM (1998). Executive function in first-episode schizophrenia. Psychol Med 28: 463-473.
36. Hyman SE, Fenton WS (2003). Medicine. What are the right targets for psychopharmacology? Science 299: 350-351.
37. Ishizuka T, Sakamoto Y, Sakurai T, Yamatodani A (2003). Modafinil increases histamine release in the anterior hypothalamus of rats. Neurosci Lett 339: 143-146.
38. Jogems-Kosterman BJ, Zitman FG, Van Hoof JJ, Hulstijn W (2001). Psychomotor slowing and planning deficits in schizophrenia. Schizophr Res 48: 317-333.
39. Joint Formulary Committee (2003). British National Formulary, 46th edn. British Medical Association and Royal Pharmaceutical Society of Great Britain: London.
40. Joyce E, Hutton S, Ambery F, Robbins TW, Barnes TRF (1999). Improvement or deterioration in different executive cognitive processes early in the course of schizophrenia. Schizophr Res 36: 138.
41. Joyce E, Hutton S, Mutsatsa S, Gibbins H, Webb E, Paul S et al (2002). Executive dysfunction in first-episode schizophrenia and relationship to duration of untreated psychosis: the West London Study. Br J Psychiatry Suppl 43: s38-s44.
42. Keefe RS, Silva SG, Perkins DO, Lieberman JA (1999). The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis. Schizophr Bull 25: 201-222.
43. Kolb B, Whishaw IQ (1983). Performance of schizophrenic patients on tests sensitive to left or right frontal, temporal, or parietal function in neurological patients. J Nerv Ment Dis 171: 435-443.
44. Levy DL, Smith M, Robinson D, Jody D, Lerner G, Alvir J et al (1993). Methylphenidate increases thought disorder in recent onset schizophrenics, but not in normal controls. Biol Psychiatry 34: 507-514.
45. Lin JS, Hou Y, Jouvet M (1996). Potential brain neuronal targets for amphetamine-, methylphenidate-, and modafinil-induced wakefulness, evidenced by c-fos immunocytochemistry in the cat. Proc Natl Acad Sci USA 93: 14128-14133.
46. Lin JS, Roussel B, Akaoka H, Fort P, Debilly G, Jouvet M (1992). Role of catecholamines in the modafinil and amphetamine induced wakefulness, a comparative pharmacological study in the cat. Brain Res 591: 319-326.
47. Logan GD (1994). On the ability to inhibit thought and action. In: Carr TH (ed). Inhibitory Processes in Attention, Memory and Language. Academic Press: San Diego. pp 189-239.
48. Makela EH, Miller K, Cutlip II WD (2003). Three case reports of modafinil use in treating sedation induced by antipsychotic medications. J Clin Psychiatry 64: 485-486.
49. McGurk SR (1999). The effects of clozapine on cognitive functioning in schizophrenia. J Clin Psychiatry 60(Suppl 12): 24-29.
50. McKenna PJ, Tamlyn D, Lund CE, Mortimer AM, Hammond S, Baddeley AD (1990). Amnesic syndrome in schizophrenia. Psychol Med 20: 967-972.
51. Mehta MA, Sahakian BJ, McKenna PJ, Robbins TW (1999). Systemic sulpiride in young adult volunteers simulates the profile of cognitive deficits in Parkinson's disease. Psychopharmacology (Berl) 146: 162-174.
52. Mitchell RL, Elliott R, Woodruff PW (2001). fMRI and cognitive dysfunction in schizophrenia. Trends Cogn Sci 5: 71-81.
53. Narendran R, Young CM, Valenti AM, Nickolova MK, Pristach CA (2002). Is psychosis exacerbated by modafinil? Arch Gen Psychiatry 59: 292-293.
54. Nelson H (1982). National Adult Reading Test Manual. Windsor NFER-Nelson: UK.
55. Oosterlaan J, Logan GD, Sergeant JA (1998). Response inhibition in AD/HD, CD, comorbid AD/HD+CD, anxious, and control children: a meta-analysis of studies with the stop task. J Child Psychol Psychiatry 39: 411-425.
56. Owen AM, Downes JJ, Sahakian BJ, Polkey CE, Robbins TW (1990). Planning and spatial working memory following frontal lobe lesions in man. Neuropsychologia 28: 1021-1034.
57. Owen AM, Roberts AC, Hodges JR, Summers BA, Polkey CE, Robbins TW (1993). Contrasting mechanisms of impaired attentional set-shifting in patients with frontal lobe damage or Parkinson's disease. Brain 116(Part 5): 1159-1175.
58. Owen AM, Sahakian BJ, Semple J, Polkey CE, Robbins TW (1995). Visuo-spatial short-term recognition memory and learning after temporal lobe excisions, frontal lobe excisions or amygdalohippocampectomy in man. Neuropsychologia 33: 1-24.
59. Pantelis C, Barber FZ, Barnes TR, Nelson HE, Owen AM, Robbins TW (1999). Comparison of set-shifting ability in patients with chronic schizophrenia and frontal lobe damage. Schizophr Res 37: 251-270.
60. Pantelis C, Brewer W (1995). Neuropsychological and olfactory dysfunction in schizophrenia: relationship of frontal syndromes to syndromes of schizophrenia. Schizophr Res 17: 35-45.
61. Robbins TW, James M, Owen AM, Sahakian BJ, McInnes L, Rabbitt P (1994). Cambridge neuropsychological test automated battery (CANTAB): a factor analytic study of a large sample of normal elderly volunteers. Dementia 5: 266-281.
62. Rogers RD, Blackshaw AJ, Middleton HC, Matthews K, Hawtin K, Crowley C et al (1999). Tryptophan depletion impairs stimulus-reward learning while methylphenidate disrupts attentional control in healthy young adults: implications for the mono-aminergic basis of impulsive behaviour. Psychopharmacology (Berl) 146: 482-491.
63. Rubia K, Russell T, Bullmore ET, Soni W, Brammer MJ, Simmons A et al (2001). An fMRI study of reduced left prefrontal activation in schizophrenia during normal inhibitory function. Schizophr Res 52: 47-55.
64. Scammell TE, Estabrooke IV, McCarthy MT, Chemelli RM, Yanagisawa M, Miller MS et al (2000). Hypothalamic arousal regions are activated during modafinil-induced wakefulness. J Neurosci 20: 8620-8628.
65. Sevy S, Davidson M (1995). The cost of cognitive impairment in schizophrenia. Schizophr Res 17: 1-3.
66. Sharma RP, Javaid JI, Pandey GN, Janicak PG, Davis JM (1991). Behavioral and biochemical effects of methylphenidate in schizophrenic and nonschizophrenic patients. Biol Psychiatry 30: 459-466.
67. Spaulding WD, Fleming SK, Reed D, Sullivan M, Storzbach D, Lam M (1999). Cognitive functioning in schizophrenia: implications for psychiatric rehabilitation. Schizophr Bull 25: 275-289.
68. Spohn HE, Strauss ME (1989). Relation of neuroleptic and anticholinergic medication to cognitive functions in schizophrenia. J Abnorm Psychol 98: 367-380.
69. Stuss DT, Benson DF, Kaplan EF, Weir WS, Naeser MA, Lieberman I et al (1983). The involvement of orbitofrontal cerebrum in cognitive tasks. Neuropsychologia 21: 235-248.
70. Szeszko PR, Bilder RM, Dunlop JA, Walder DJ, Lieberman JA (1999). Longitudinal assessment of methylphenidate effects on oral word production and symptoms in first-episode schizophrenia at acute and stabilized phases. Biol Psychiatry 45: 680-686.
71. Taylor FB, Russo J (2000). Efficacy of modafinil compared to dextroamphetamine for the treatment of attention deficit hyperactivity disorder in adults. J Child Adolesc Psychopharmacol 10: 311-320.
72. Taylor MA, Abrams R (1987). Cognitive impairment patterns in schizophrenia and affective disorder. J Neurol Neurosurg Psychiatry 50: 895-899.
73. Turner DC, Clark L, Dowson J, Robbins TW, Sahakian BJ (2004). Modafinil improves cognition and response inhibition in adult ADHD. Biol Psychiatry, (in press).
74. Turner DC, Robbins TW, Clark L, Aron AR, Dowson J, Sahakian BJ (2003a). Cognitive enhancing effects of modafinil in healthy volunteers. Psychopharmacology (Berl) 165: 260-269.
75. Turner DC, Robbins TW, Clark L, Aron AR, Dowson J, Sahakian BJ (2003b). Relative lack of cognitive effects of methylphenidate in elderly male volunteers. Psychopharmacology (Berl) 168: 455-464.
76. Wechsler D (1981). Wechsler Adult Intelligence Scale - Revised. The Psychological Corporation: New York.
77. Weinberger DR, Berman KF, Zee RF (1986). Physiologic dysfunction of dorsolateral prefrontal cortex in schizophrenia. I. Regional cerebral blood flow evidence. Arch Gen Psychiatry 43: 114-124.
78. Wisor JP, Nishino S, Sora I, Uhl GH, Mignot E, Edgar DM (2001). Dopaminergic role in stimulant-induced wakefulness. J Neurosci 21: 1787-1794.
79. Wong YN, King SP, Laughton WB, McCormick GC, Grebow PE (1998). Single-dose pharmacokinetics of modafinil and methylphenidate given alone or in combination in healthy male volunteers. J Clin Pharmacol 38: 276-282.
80. Wykes T, Reeder C, Corner J (2000). The prevalence and stability of an executive processing deficit, response inhibition, in people with chronic schizophrenia. Schizophr Res 46: 241-253.
81. Wykes T, Reeder C, Corner J, Williams C, Everitt B (1999). The effects of neurocognitive remediation on executive processing in patients with schizophrenia. Schizophr Bull 25: 291-307.
82. Wykes T, Reeder C, Williams C, Corner J, Rice C, Everitt B (2003). Are the effects of cognitive remediation therapy (CRT) durable? Results from an exploratory trial in schizophrenia. Schizophr Res 61: 163-174.
83. Yu BP, Maguire GA, Liffick TF (2002). Modafinil for treatment of the negative symptoms of schizophrenia and antipsychotic-induced sedation. Sleep 25: A503-A504.